To date, the company has in-licensed rights
relating to product candidates in clinical development for the
treatment of CNS disorders, including chorea associated with
Huntington's Disease, Parkinson's disease and schizophrenia. Formation of the Center was prompted by the completion of the
Human Genome Project and the increasingly prominent role that Medical Genetics
will therefore play in human health care. is responsible for Japan. The most
commonly reported SAEs were pyrexia (6%), diarrhea (5% ), dyspnea and pneumonia
(4%) and vomiting (3%).millennium.

Contacts:
Adriana Jenkins (Media) Kyle Kuvalanka (Investor Relations)
617-761-6996 617-761-4734

epidermal bucy

In October 2004, Prestwick announced the results of its Phase III
study of tetrabenazine for chorea associated with Huntington's
Disease. The discipline
of Medical Genetics is now empowered with tools which will help us screen
individuals and populations at risk for DNA variations and mutations and
thereby predict and intervene to prevent possible serious genetic disorders in
their offspring and themselves," said Dr. Macdonald Foundation at the University of Miami Miller School
of Medicine .tmbioscience.com/cgi-bin/prnh/19991220/MLNMLOGO )
The U. This indication doubles the number of U. EST on Tuesday, March 29,
2005, from The Mayflower Hotel in Washington, DC.
Janssen Pharmaceutical K. The Company's research, development and commercialization
activities are focused in three therapeutic areas: oncology, cardiovascular
and inflammation.

toxoplasmosis typhus

Nine patients (30%)
discontinued tetrabenazine due to behavior changes (3), sedation (3),
worsening or lack of improvement in movements (2) and major depression
(1).

Tm Bioscience to supply the University of Miami's Dr. John T. Macdonald Foundation Center for Medical Genetics with Tag-It(TM) reagents

Macdonald Foundation Center for Medical Genetics .edu

About Tag-It(TM) reagents and genetic tests
Tm Bioscience's product menu is focused in the fields of human genetic
disorders, pharmacogenetics and infectious disease.com.
VELCADE is being co-developed by Millennium and Johnson + Johnson
Pharmaceutical Research + Development, L.
VELCADE is being co-developed by Millennium and Johnson + Johnson
Pharmaceutical Research + Development, L.3 mg/m2 dose in the phase
III APEX study, the most commonly reported adverse events were asthenic
conditions (61%), diarrhea (57%), nausea (57%), constipation (42%), peripheral
neuropathy (36%), vomiting (35%), pyrexia (35%), thrombocytopenia (35%),
psychiatric disorders (35%) and anorexia and appetite decreased (34%).
Editors' Note: This press release is also available under the Media
section of the Company's website at: http://www.

kluver tabes

Frucht, MD, Assistant Professor of
Neurology , Neurological Institute of New York, Columbia University
Medical, Center for Parkinson's Disease and Other Movement Disorders,
and lead investigator of the study. It is one of two signature programs launched in 2002 by
the Dr. Food and Drug Administration as an in vitro device for
diagnostic use in the United States. "The approval further demonstrates the
success of the Company's strategy to rapidly advance drugs from pipeline to
market, and then expand the indications to benefit more patients.
Risks associated with VELCADE therapy include new or worsening peripheral
neuropathy , hypotension, cardiac disorders, gastrointestinal adverse events,
thrombocytopenia and tumor lysis syndrome.

tietze thrombocytopenia

3 years.
Twenty-two of the 30 patients (73%) experienced a reduction in
movements (as assessed by the examining physician) after starting
tetrabenazine. Assays from Tm operate on the Luminex xMAP(R) system, a
well-established bead based instrument.L.; Ortho Biotech and Janssen-Cilag are
responsible for commercialization in Europe and the rest of the world. A total of 144 patients on VELCADE
(44%) reported serious adverse events (SAEs) during the study.

thalassemia staphylococcal

Tetrabenazine is not FDA -approved for
marketing in the United States.

Prestwick Pharmaceuticals

Prestwick Pharmaceuticals , Inc.

The Company has
commercialized Analyte Specific Reagents(x) and a series of Tag -It(TM)
tests(xx) for a variety of genetic disorders.

About Tm Bioscience - Putting the Human Genome to Work(TM)
Tm Bioscience is a DNA-based diagnostics company developing a suite of
genetic tests. patients
who could potentially benefit from VELCADE to approximately 22,000 .com.
For a further list and description of the risks and uncertainties the Company
faces, see the reports it has filed with the Securities and Exchange
Commission.

epidermal thalassemia

John T. "We are pleased to be supplying the Center
with our reagents and look forward to working with them to provide reagents
that can be incorporated into a comprehensive and beneficial screening
program.medgen. Combined , the Universal Array and
Luminex instrument enable the rapid production of flexible, high-throughput ,
low-cost DNA-based tests. Analytical and performance characteristics
are not established ., Millennium
Pharmaceuticals, Inc. is responsible for Japan., markets VELCADE, a novel cancer product , co-
promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading
cardiovascular product and has a robust clinical development pipeline of
product candidates.

tietze tabes

The study was approved by the
medical center's institutional review board, and neither the study nor
the investigators were supported by Prestwick. Side effects can include drowsiness,
insomnia, akathisia and depression.

The company
anticipates filing a New Drug Application (NDA) for tetrabenazine with
the U. Food and Drug Administration (FDA) approved the Company's
supplemental New Drug Application (sNDA) for VELCADE on March 25, 2005, less
than two years after the initial accelerated approval for relapsed and
refractory MM was granted.
VELCADE is currently approved in more than 40 countries around the world, for
treatment of multiple myeloma (MM) patients who have received at least two
prior therapies and have demonstrated disease progression on the last therapy.

This press release contains "forward-looking statements," including
statements about the Company's growth, future operating results, discovery,
development of products and strategic alliances.

tmd tyrosinemia

(x) Analyte Specific Reagent. Women of childbearing potential
should avoid becoming pregnant while being treated with VELCADE.

torticollis takatsuki

Louis Elsas, Director of The
Dr. The Center is a pioneering
initiative for comprehensive genetic resources that combines Research,
Education and Service. Additional information about Tm Bioscience can be found
at http://www. It can be accessed by visiting the
Investors section of the Company's website, http://www.S.
Fourteen percent of patients reported at least one episode of grade 4
toxicity; the most common grade 4 toxicities were thrombocytopenia (4%),
neutropenia (2%) and hypercalcemia (2%).
For more information about VELCADE clinical trials, patients and
physicians can contact the Millennium Medical Product Information Department
at 1-866-VELCADE (1-866-835-2233).

trachoma tietze

A retrospective chart review was conducted to assess the efficacy
and tolerability of tetrabenazine among these patient populations. Macdonald Foundation Center is an international center
of excellence and serves a large and diverse population," said Greg Hines,
President and CEO of Tm Bioscience. Genetics is unique in that it
reaches into every aspect of human health and is the root cause of many major
and minor diseases.S.

dorsalis thalassemia

Frucht. By enabling presymptomatic disease diagnosis and providing
the means of intervention, the health care discipline of Medical Genetics
makes it possible to prevent the onset of disease, thus maintaining health,
prolonging life and lowering the cost of treatment. The event will be webcast
live and will be archived for 30 days.K.

epidermal multiforme

New Data Reported on Tetrabenazine for the Treatment of Pediatric Hyperkinetic Movement Disorders

is a product -focused specialty
pharmaceutical company engaged in the development and
commercialization of drugs with high commercial potential and
relatively low development risk that target chronic diseases of the
central nervous system. John T. John T.
The Miami GeneCure Diagnostic laboratory is the most venerable diagnostic
laboratory in Miami.S.

takatsuki thromboangiitis

"We are encouraged by the fact
that nearly three quarters of children treated with tetrabenazine
experienced a reduction in their involuntary movements ."

Study Design and Results

Over the course of 18 years, 30 children aged 18 years and younger
were treated with tetrabenazine at Columbia University Medical Center
for a variety of hyperkinetic movement disorders, including chorea,
dystonia, and Tourette Syndrome or tics.miami .
(xx) For Investigational Use Only.newscom.S.C.; Ortho Biotech and Janssen-Cilag are
responsible for commercialization in Europe and the rest of the world.

About Millennium
Millennium Pharmaceuticals, Inc. By applying its knowledge of the human genome, its
understanding of disease mechanisms and its industrialized drug discovery
platform, Millennium is seeking to develop breakthrough products.

staphylococcal takatsuki

9 mg/kg/d)
for 1. Sixteen patients continued tetrabenazine along with at
least one other medication to control movements, while movements were
sufficiently controlled with tetrabenazine alone in six patients.

About the University of Miami's Dr. Millennium is responsible for
commercialization of VELCADE in the U.

tuberous tmd

On average,
patients were treated with a total dose of 150."

Tetrabenazine

Tetrabenazine is available in some European markets and Australia
as XENAZINE(R) and in Canada as NITOMAN(R) for the treatment of
hyperkinetic movement disorders .
"The Dr. John T. (Nasdaq: MLNM) today announced that the Company will be
focusing on the recent full approval of VELCADE in relapsed refractory
multiple myeloma (MM) at the upcoming Citigroup Smith Barney Healthcare
Conference.C.

torticollis takatsuki

Side
effects, which were ameliorated with a reduction in dose, were
experienced in nineteen patients (63%), including sedation (30%),
behavioral changes (20%), depression (10%), worsening of movements
(6%), nausea (3%) and parkinsonism (3%). "Similarly , side effects were
typically dose-dependent, and we did not observe tardive dyskinesia in
our patient population.
Prestwick was granted both fast track and orphan designation by the
FDA for tetrabenazine. Elsas, in November 2002.S.

clostridial thrombocytopenia

"The results of this pediatric study support earlier findings in
adults that suggest tetrabenazine may be an effective and
well-tolerated treatment option for severe pediatric hyperkinetic
movement disorders," said Dr. Food and Drug Administration (FDA) in the near future.

The TSX Exchange has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release.m.millennium.

About VELCADE(R) (bortezomib ) for Injection
VELCADE is indicated for the treatment of multiple myeloma patients who
have received at least one prior therapy.
Janssen Pharmaceutical K.K. The Company disclaims any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information ,
future events or otherwise.

thromboangiitis tuberous

Twenty-eight patients (93%) had tried other medications without
adequate relief prior to being placed on tetrabenazine.med. Tm Bioscience's product pipeline includes tests for genetic
disorders, drug metabolism, and infectious diseases.

Millennium to Discuss Full Approval of VELCADE(R) (bortezomib) for Injection in Second-Line Multiple Myeloma

VELCADE is contraindicated in
patients with hypersensitivity to bortezomib, boron, or mannitol.L.
In 331 patients who were treated with VELCADE 1.

thalassemia trachoma

S. John T. The performance characteristics of
these products have not been established.

typhus takatsuki

"This is one of the largest reported studies of children treated
with tetrabenazine," said Steven J. Macdonald Foundation Center for
Medical Genetics was established in July 2000, and welcomed its first
Director, Dr. Louis J. All genetic tests from Tm Bioscience are
based on the Tag-It(TM) Universal Array platform, which utilizes a proprietary
universal tag system that allows for easy optimization, product development
and expansion.

bucy thrombocytopenia

Pharmaceutical Writers/Business Editors

MIAMI BEACH, Fla. TSX: TMC

TORONTO, July 27 - Tm Bioscience Corporation
(Toronto, Ontario; TSX: TMC), a leader in the commercial genetic testing
market, today announced it has signed an agreement to supply The University of
Miami's Dr.
"Tm is to be congratulated for developing this platform. The Molecular Cytogenetics Laboratory is the only local
platform for translational research, offering comprehensive screening and
diagnostic testing for prenatal, neonatal, pediatric, and adult diseases and
conditions. Please see http://www.
(Logo: http://www.
To date, approximately 12,000 patients have been treated with VELCADE.

toxoplasmosis multiforme

--- -

Findings Presented at 57th Annual Meeting of the American Academy
of Neurology

Clinical study investigators concluded that tetrabenazine was an
effective and well-tolerated treatment for severe hyperkinetic
movement disorders among children who are resistant to other
medications, according to new data presented today at the 57th Annual
Meeting of the American Academy of Neurology in Miami Beach.9 mg/d (4. The study was conducted in adults only. The Company's Tag-It(TM) Cystic
Fibrosis Kit is the first multiplexed human disease genotyping test to be
cleared by the U. Tm Bioscience is located
in Toronto, Ontario. VELCADE is the only drug therapy that has
demonstrated a significant survival advantage as compared to a standard
therapy in relapsed MM.
"The new label recognizes the benefits of VELCADE in earlier lines of
therapy for MM patients , and we believe ongoing studies will continue to build
evidence for its potential use in the front line setting," said Mark Levin,
chief executive officer, Millennium. Various important risks may
cause the Company's actual results to differ materially from the results
indicated by these forward -looking statements, including: adverse results in
its drug discovery and clinical development programs; failure to obtain patent
protection for its discoveries; commercial limitations imposed by patents
owned or controlled by third parties; the Company's dependence upon strategic
alliance partners to develop and commercialize products and services based on
its work; difficulties or delays in obtaining regulatory approvals to market
products and services resulting from its development efforts; product
withdrawals; competitive factors; difficulties or delays in manufacturing the
Company's products; government and third party reimbursement rates; the
commercial success of VELCADE and INTEGRILIN; achieving revenue consistent
with internal forecasts; and the requirement for substantial funding to
conduct research and development and to expand commercialization activities.

trematodes tyrosinemia

Macdonald Foundation Center for Medical Genetics (Miami,
Florida) with reagents for use in its Cystic Fibrosis and Ashkenazi Jewish
Panel gene assays. John T. Macdonald Foundation Center
for Medical Genetics
The University of Miami's Dr."
Millennium management will present at 3:55 p. Millennium is responsible for
commercialization of VELCADE in the U.com.

thalassemia takatsuki

"
Tag-It(TM) ASR(x) reagents from Tm Bioscience will be used in the
Center's Cystic Fibrosis gene assay, which detects multiple mutations
associated with CF, and in its Ashkenazi Jewish Panel gene assay, which
detects gene mutations associated with Tay-Sachs disease, Canavan Disease,
Familial Dysautonomia, Gaucher Disease, Bloom Syndrome, Fanconi Anemia,
Neimann-Pick Disease, and Mucolipidosis Type IV. - Significant survival advantage and next steps for VELCADE are among
highlights of presentation at Citigroup Smith Barney Healthcare Conference -

CAMBRIDGE, Mass. Management will discuss the significant survival advantage that
was demonstrated in a phase III study comparing VELCADE to a standard therapy,
the results of which led to the expanded label in the treatment of patients
with MM who have received at least one prior therapy., a leading biopharmaceutical company
based in Cambridge, Mass.

clostridial trematodes

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)